Salut Sant Joan De Reus

At Salut Sant Joan De Reus, the Oncology program is centered on neoplasms, with a strong focus on breast cancer and other solid tumors. The trials are largely designed to test new treatment options, improve outcomes after standard therapy, and refine strategies for earlier detection of recurrence.

• Advanced and early-stage breast cancer, including HER2-positive, HR-positive/HER2-negative, and triple-negative breast cancer
• Metastatic solid tumors and neoplasm metastasis, with studies aimed at improving disease control
• Evaluation of newer targeted and immune-based therapies to strengthen treatment effectiveness

This research landscape also includes studies on treatment resistance, relapse risk, and biomarker-guided care, reflecting a broad effort to personalize cancer therapy and improve long-term outcomes for patients.

A major share of the clinical trial activity at this site involves breast neoplasms, spanning early, locally advanced, and metastatic disease. Research is focused on testing novel endocrine, HER2-targeted, antibody-drug conjugate, and immunotherapy approaches to improve survival and reduce recurrence.

• HER2-positive breast cancer and HER2-negative breast cancer across multiple stages
• Hormone receptor-positive disease, including endocrine-resistant and ESR1-mutated cases
• Triple-negative breast cancer studies assessing new ways to improve response and prevent relapse

Several trials at Salut Sant Joan De Reus also explore biomarker-driven approaches, helping identify which patients may benefit most from specific therapies and supporting more individualized treatment planning.

The site contributes to research in male urogenital diseases and urinary bladder neoplasms, with trials covering both prostate and bladder cancer. These studies aim to improve cancer control, reduce recurrence, and expand options for patients with difficult-to-treat disease.

• Prostate cancer, including high-risk localized and metastatic forms
• Non-muscle invasive bladder cancer and muscle-invasive bladder cancer
• Studies evaluating better treatment combinations and bladder-preserving approaches

This area of research reflects a strong interest in both earlier intervention and more effective management of advanced disease, with the goal of improving disease-free and progression-free outcomes.

Clinical trials in respiratory tract diseases at this hospital include research on non-small cell lung cancer and severe inflammatory lung conditions. The studies are intended to test new therapies, improve response rates, and support better management of advanced or surgically treated disease.

• Non-small cell lung cancer, including resectable and metastatic disease
• Molecularly defined subgroups such as RET fusion-positive and ROS1-positive lung cancer
• Acute respiratory distress syndrome linked to pneumonia or other infections

The research portfolio combines oncology and critical care, showing interest in both precision cancer treatment and supportive approaches for serious respiratory illness.

Beyond oncology, the site also supports trials in cardiovascular diseases and nutritional and metabolic diseases. These studies focus on lowering cardiovascular risk, improving cholesterol and lipid disorders, and evaluating therapies that may prevent major heart and vascular events.

• Atherosclerotic cardiovascular disease and primary prevention of cardiovascular events
• Hypercholesterolemia, elevated lipoprotein(a), and severe hypertriglyceridemia
• Assessment of newer treatments aimed at better long-term risk reduction

This research helps broaden the clinical trial profile at Salut Sant Joan De Reus, linking cancer care with important chronic disease prevention efforts.

The clinical trial portfolio also includes studies in physiological processes and related treatment-support areas, covering conditions that affect quality of life and treatment tolerance. These trials are designed to improve symptom control, support safer cancer therapy, and explore new ways to manage complications of treatment.

• Chemotherapy-induced thrombocytopenia, nausea, and vomiting
• Drug-related side effects and adverse reactions during cancer treatment
• Research into metabolic and biologic markers that may help guide care

Overall, this reflects a practical and patient-centered approach to clinical research, with attention to both disease treatment and the supportive care needed to make therapy more effective and manageable.